MARKET

CPHHF

CPHHF

Cinclus Pharma H
Grey
--
NaN%
Closed
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
No Data
About CPHHF
Cinclus Pharma Holding AB (publ) (Cinclus Pharma) is a Sweden-based research based biotech company developing small molecules for the treatment of gastric acid related diseases. The Company is developing linaprazan glurate, which is being developed for the treatment of severe gastroesophageal reflux disease (GERD). The Company's mission is to introduce products impacting standard of care for patients with gastric acid related diseases, underpinned by the superior P-CAB linaprazan glurate. Cinclus Pharma is in an intensive development phase, ramping up the organization and company structure to prepare for growth and the further development of linaprazan glurate. Cinclus Pharma owns the worldwide commercial rights for linaprazan glurate. Secured commercial rights are central in utilizing the process of launching the product in markets worldwide.

Webull offers Cinclus Pharma Holding publ AB stock information, including Grey: CPHHF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPHHF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CPHHF stock methods without spending real money on the virtual paper trading platform.